产品说明书

Ticlopidine

Print
Chemical Structure| 55142-85-3 同义名 : PCR 5332
CAS号 : 55142-85-3
货号 : A269629
分子式 : C14H14ClNS
纯度 : 99%+
分子量 : 263.786
MDL号 : MFCD00661081
存储条件:

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(398.05 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Ticlopidine is a selective and the first FDA-approved P2Y12 antagonist which can affect platelet aggregation when. It can be metabolized through cytochrome P450 in the liver and forms the active thienopyridine metabolites. The thienopyridine metabolites can irreversibly antagonize the P2Y12 receptor[3]. This results in inhibition of the binding of the P2Y12 agonist 2-methylthio-ADP and the ADP-induced downregulation of adenylyl cyclase[4].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00889044 Platlet Aggregation ... 展开 >> Major Bleeding Outcomes 收起 << Phase 3 Unknown June 2011 Israel ... 展开 >> Sheba_medical_center Not yet recruiting Ramat-Gan, Israel Contact: Shlomo Matetzky, M.D    972-3-5302504    Shlomi.Matetzky@sheba.health.gov.il    Sub-Investigator: Elad Asher, M.D          Sheba Medical Center, Cardiac Institute Recruiting Tel Hashomer, Israel Contact: Shlomi Matetzky, MD    972-3-530-2504    shlomi.matetzky@sheba.health.gov.il    Contact: Elad Asher, MD    972-3-530-2504    elad.asher@sheba.health.gov.il 收起 <<
NCT00853450 Antiplatelet Effect Phase 1 Completed - Sweden ... 展开 >> Research Site Lund, Sweden 收起 <<
NCT00944333 Angina Pectoris ... 展开 >> Silent Ischemia 收起 << Phase 3 Terminated(STOP due to recent ... 展开 >>data in literature questioning the need to continue DAP beyond six months in patients with stable coronary artery stenting with DES.) 收起 << - Italy ... 展开 >> Irccs Fondazione Centro S. Raffaele Del Monte Tabor - Milano (mi), Italy, 20132 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.79mL

0.76mL

0.38mL

18.95mL

3.79mL

1.90mL

37.91mL

7.58mL

3.79mL

参考文献

[1]Michelson AD, et al. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s33-8.

[2]Savi P, Herbert JM, et al. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 Apr;31(2):174-83.

[3]Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s33-8. doi: 10.1161/ATVBAHA.107.160689. Epub 2008 Jan 3. PMID:18174449.

[4]Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 Apr;31(2):174-83. doi: 10.1055/s-2005-869523. PMID: 15852221.